The co-crystallization of indigoids with CDK2 reveals many details about the atomic interactions of the inhibitors with the CDK, and will be helpful in the synthesis of new, and hopefully potent ...

This growth is driven by a rise in cancer diagnoses, promising results from early-phase clinical trials of CDK inhibitors such as Samuraciclib and Q901, and the growing number of these inhibitors ...

Genentech is strengthening its oncology pipeline by acquiring Regor Pharmaceuticals’ portfolio of breast cancer ...

Cambridge, Massachusetts-based biotech Regor Therapeutics Group has agreed to sell its portfolio of CDK inhibitors for the treatment of breast cancer to Roche's Genentech for an upfront cash ...

for a portfolio of CDK inhibitors for treating breast cancer. Genentech will be responsible for clinical development, manufacturing, and commercialization; Regor will manage the two ongoing Phase ...

A TYK Medicines Inc. patent discloses tricyclic compounds acting as CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.

Per the agreement, Roche’s Genentech will acquire Regor’s portfolio of next-generation CDK inhibitors for the treatment of breast cancer. The purchase agreement was announced at Roche’s ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...